Board Member
IDEAYA Biosciences, Inc. (IDYA)Equibles does not estimate personal net worth.
Get an email with a short summary when IDEAYA Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get IDYA alertsYujiro Hata is recorded as Board Member at IDEAYA Biosciences, Inc. (IDYA) since January 1, 2015 and CEO at IDEAYA Biosciences, Inc. (IDYA). The newest filing on record that lists Yujiro Hata as CEO and Board Member at IDEAYA Biosciences, Inc. (IDYA) is dated April 29, 2026. The proxy statement of IDEAYA Biosciences, Inc. reports total compensation of $9,512,640 for Yujiro Hata in fiscal 2025, including a base salary of $700,000. Disclosed compensation is on record for 8 fiscal years. Yujiro Hata has spoken on 1 earnings call and 4 other investor events across 1 company, most recently for IDEAYA Biosciences, Inc. on September 10, 2026. IDEAYA Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at IDEAYA Biosciences, Inc. includes Joshua Bleharski (CFO), Joshua Bleharski, Ph.D. (CFO), Andres Ruiz Briseno (Chief Accounting Officer and Head of Investor Relations) and 7 others.
“First, thank you, Yagol, for the introduction, and thank you to Citi for the invitation to participate against this year. So, I did Biosciences. We're a leading precision medicine oncology company.”
“Yeah, so Daruva Seratib, for those maybe less familiar with the company, has been in a front-line registrational study of metastatic uva melanoma. We did receive our tour, so we've been through the NDA pre-submission module process.”
“Yeah, so I think the short answer is no. I think very unlikely, and I'm not sure that's the objective either to cure all diseases with AI.”
“So, Maury, thanks for the introduction, and thank you to Jeffries for the opportunity to participate at your annual global health care conference. So, Maury, as you noted, in terms of IDEA, we did have an announcement this morning, which we'll cover.”
“I'll be making some forward-looking statements today. And today we're absolutely thrilled to provide a program update on IDE397, as well as our Q1 2022 earnings update.”
2015-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
CEO, Board Member
2015-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $700,000 | $9,512,640 |
| 2024 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $646,000 | $16,930,872 |
| 2023 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $598,000 | $5,995,440 |
| 2022 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $570,000 | $3,327,004 |
| 2021 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $543,600 | $3,848,871 |
| 2020 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $509,800 | $1,777,811 |
| 2019 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $457,150 | $2,020,989 |
| 2018 | IDEAYA Biosciences, Inc. (IDYA) | President and Chief Executive Officer | $420,000 | $2,262,701 |
